文献速递银屑病与炎症性皮肤病皮肤肿瘤

IL-17与IL-23抑制剂与恶性肿瘤风险的国际人群研究

Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2023-10-04

基于全球人群的队列研究比较银屑病患者使用IL-17i、IL-23i与TNFi后5年内恶性肿瘤风险。结果显示IL-17i与多种恶性肿瘤风险降低相关,IL-23i与NHL、肝胆癌和BCC风险降低相关。

要点

  • IL-17i组非霍奇金淋巴瘤风险低于TNFi组(HR 0.58)。
  • IL-17i组黑色素瘤和基底细胞癌风险低于TNFi组(HR 0.52和0.57)。
  • IL-23i组非霍奇金淋巴瘤风险低于TNFi组(HR 0.39)。

核心结论

  • IL-17i和IL-23i与多种恶性肿瘤风险降低相关。
  • 这些发现应在开具生物制剂前被考虑。

研究设计与样本

  • 全球人群队列研究,包含两个独立分析。
  • 分析一:IL-17i新使用者(n=15,331)对比TNFi新使用者(n=15,331)。
  • 分析二:IL-23i新使用者(n=5,832)对比TNFi新使用者(n=5,832)。
  • 评估药物启动后前5年内恶性肿瘤风险。

主要发现

  • IL-17i组非霍奇金淋巴瘤风险低于TNFi组(HR 0.58,95% CI 0.40-0.82,p=0.002)。
  • IL-17i组结直肠癌风险低于TNFi组(HR 0.68,95% CI 0.49-0.95,p=0.024)。
  • IL-17i组肝胆癌风险低于TNFi组(HR 0.68,95% CI 0.58-0.80,p<0.001)。
  • IL-17i组卵巢癌风险低于TNFi组(HR 0.48,95% CI 0.29-0.81,p=0.005)。
  • IL-17i组黑色素瘤风险低于TNFi组(HR 0.52,95% CI 0.37-0.73,p<0.001)。

关键数值与推荐

  • IL-17i组基底细胞癌风险低于TNFi组(HR 0.57,95% CI 0.48-0.67,p<0.001)。
  • IL-23i组非霍奇金淋巴瘤风险低于TNFi组(HR 0.39,95% CI 0.19-0.78,p=0.006)。
  • IL-23i组肝胆癌风险低于TNFi组(HR 0.44,95% CI 0.31-0.62,p<0.001)。
  • IL-23i组基底细胞癌风险低于TNFi组(HR 0.76,95% CI 0.57-0.99,p=0.046)。
  • 敏感性分析中,IL-17i和IL-23i与生物制剂初治患者相比,与多种恶性肿瘤风险降低相关。

临床怎么用

  • 这些发现应在开具生物制剂前被考虑。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancer risk after long-term exposure to interleukin (IL)-23 inhibitors (IL-23i) and IL-17 inhibitors (IL-17i) remains to be delineated. OBJECTIVE: To evaluate the risk of malignancies in patients with psoriasis treated with IL-23i and IL-17i relative to those prescribed tumour necrosis factor inhibitors (TNFi) during the first 5 years following drug initiation. METHODS: A global population-based cohort study included two distinct analyses comparing patients with psoriasis under different therapeutic modalities; (i) new users of IL-17i(n = 15,331) versus TNFi (n = 15,331) and (ii) new users of IL-23i (n = 5832) versus TNFi (n = 5832). RESULTS: Patients prescribed IL-17i experienced a decreased risk of non-Hodgkin lymphoma (NHL; HR, 0.58; 95% CI, 0.40-0.82; p = 0.002), colorectal cancer (HR, 0.68; 95% CI, 0.49-0.95; p = 0.024), hepatobiliary cancer (HR, 0.68; 95% CI, 0.58-0.80; p < 0.001), ovary cancer (HR, 0.48; 95% CI, 0.29-0.81; p = 0.005), melanoma (HR, 0.52; 95% CI, 0.37-0.73; p < 0.001), and basal cell carcinoma (BCC; HR, 0.57; 95% CI, 0.48-0.67; p < 0.001). IL-23i was associated with a reduced risk of NHL (HR, 0.39; 95% CI, 0.19-0.78; p = 0.006), hepatobiliary cancer (HR, 0.44; 95% CI, 0.31-0.62; p < 0.001) and BCC (HR, 0.76; 95% CI, 0.57-0.99; p = 0.046). In a sensitivity analysis comparing patients managed by IL-17i and IL-23i with their biologic-naïve counterparts, these classes were associated with decreased risk of several malignancies. CONCLUSION: IL-17i and IL-23i are associated with decreased risk of several malignancies. These findings should be considered prior to the prescription of biologics.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Kridin K, Abdelghaffar M, Mruwat N, et al. Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?-Insights from an international population-based study. J Eur Acad Dermatol Venereol. 2023. PMID: 37730962. doi:10.1111/jdv.19520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。